![]() |
|
|
Vol. 286, Issue 1, 354-361, July 1998
Department of Biopharmaceutical Sciences, University of California, San Francisco, San Francisco, California
| |
Abstract |
|---|
|
|
|---|
Recently, a polyspecific organic cation transporter, hOCT1, was cloned from human liver. To date, limited studies examining the functional characteristics of the transporter have been performed. The purpose of the present study was to develop a mammalian expression system for hOCT1 and to characterize the interactions of various compounds with the cloned transporter. Lipofection was used to transiently transfect the hOCT1 plasmid DNA in a human cell line, HeLa. We tested the interaction of an array of organic cations and other compounds with hOCT1 by determining Ki values in inhibiting C-tetraethylammonium (TEA) transport in the transfected cells. Transient expression of hOCT1 activity was observed between 24 and 72 hr post-transfection, with maximal expression at approximately 40 hr. TEA transport was temperature dependent and saturable with Vmax and Km values of 2.89 ± 0.448 nmol/mg protein/30 min and 229 ± 78.4 µM, respectively. 14C-TEA uptake in hOCT1 plasmid DNA-transfected HeLa cells was trans-stimulated by unlabeled TEA and 1-methyl-4-phenyl-pyridinium. Organic cations, including clonidine, quinine, quinidine and verapamil (0.1 mM), significantly inhibited 14C-TEA uptake, whereas the organic anion, p-aminohippuric acid (5 mM), did not. The neutral compounds, corticosterone (Ki, 7.0 µM) and midazolam (Ki, 3.7 µM) potently inhibited 14C-TEA uptake. The Ki values of several compounds in interacting with hOCT1 differed substantially from the corresponding values for the rat organic cation transporter, rOCT1, and the human kidney-specific organic cation transporter, hOCT2, determined in previous studies. Transiently transfected HeLa cells represent a useful tool in studying the interactions and kinetics of organic cations and other xenobiotics with hOCT1 and in understanding the molecular events involved in organic cation transport.
| |
Introduction |
|---|
|
|
|---|
Organic
cations are positively charged amines under physiological pH. Drugs
from a wide array of clinical classes including antihistamines
(e.g., cimetidine), antiarrhythmics (e.g.,
procainamide), skeletal muscle relaxants (e.g., vecuronium)
and beta adrenoceptor blocking agents (e.g.,
acebutolol), as well as endogenous bioactive amines such as dopamine,
NMN and choline are organic cations. These polar molecules are
transported across epithelia by carrier-mediated processes. Based on
previous studies in isolated plasma membrane vesicles and intact tissue
preparations, a three-step model for the secretory flux of organic
cations across various epithelia has been proposed: an electrogenic,
facilitated diffusion step at the basolateral membrane, intracellular
sequestration, and a proton or an organic cation exchange mechanism at
the apical side (Pritchard and Miller, 1993
; Zhang et al.,
1998
).
The first organic cation transporter, rOCT1, was cloned in 1994 from
rat kidney (Grundemann et al., 1994
). Since then several organic cation transporters have been cloned from various species and
tissues (Gorboulev et al., 1997
; Grundemann et
al., 1997
; Ikumi et al., 1997
, Okuda et al.,
1996
; Terashita et al., 1998
; Zhang et al.,
1997a
, b
). Recently, we and others cloned a human organic cation
transporter, hOCT1, from liver by homology cloning methods (Gorboulev
et al., 1997
; Zhang et al., 1997b
). Initial functional expression studies carried out in Xenopus laevis
oocytes (Zhang et al., 1997b
) demonstrated that hOCT1,
similar to rOCT1, is polyspecific with respect to substrate
selectivity. Namely, the prototype organic cations, TEA and
MPP+, are its permeants (substrates). In
addition, both small and bulkier organic cations as well as other
compounds such as nucleosides and bile acids inhibit the transport of
MPP+ mediated by hOCT1 (Zhang et al.,
1997b
). Northern blot analysis indicates that the mRNA transcripts of
hOCT1 are expressed primarily in the liver; however, reverse
transcriptase polymerase chain reaction analysis demonstrates that
hOCT1 mRNA transcripts also are expressed in lower abundance in the
human kidney and intestine as well as in other tissues (Gorboulev
et al., 1997
; Zhang et al., 1997b
).
X. laevis oocytes have been used extensively in elucidating
the functional characteristics of transport proteins (Giacomini et al., 1994
; Gorboulev et al., 1997
; Grundemann
et al., 1994
; Murer and Biber, 1997
; Okuda et
al., 1996
; Sigel, 1990
; Terashita et al., 1998
; Zhang
et al., 1997a
, b
). Although the oocyte expression system has
important advantages for studying transporters, it also has major
disadvantages which limit its use particularly for routine studies of
drug transport and in high throughput screening of drugs. Notably,
oocytes are subject to seasonal variability in their viability as well
as in their protein translation function. mRNA which is very unstable
needs to be transcribed in vitro before being injected into
oocytes. Moreover, injecting mRNA into oocytes requires tedious
micro-injection techniques and specialized equipment. In contrast,
mammalian expression systems do not require the in vitro
handling of mRNA and are adapted more readily to routine use in drug
screening processes. Recently, mammalian expression systems have been
developed and used in expressing several transport proteins (Boyer
et al., 1994
; Cardarelli et al., 1995
; Clark and Amara, 1994
; Martel et al., 1996
; Risso et al.,
1996
; Schaner et al., 1997
; Varoqui et al.,
1996
). For organic cation transporters, the human embryonic kidney
(HEK) 293 cell line has been used to study the function of rOCT1
(Martel et al., 1996
) and OCT2p, a second member of the OCT
family cloned from LLCPK1 cells (Grundemann et al., 1997
).
The goal of this study was to develop a mammalian cell expression
system for hOCT1 and to elucidate the functional characteristics of the
transporter in this cell line. Specifically, we determined the potency
of various organic cations and other compounds in interacting with
hOCT1. In addition, we examined the stereoselectivity of hOCT1 with the
enantiomers of disopyramide and the diastereomers, quinine and
quinidine. Finally, we determined whether the transporter can operate
bidirectionally as an organic cation/organic cation exchanger. Our data
represent the first demonstration of functional expression of a human
organic cation transporter in a mammalian cell line (HeLa). A
comparison of the data obtained in this study with data in the
literature suggests that there are notable differences in the intrinsic
function of hOCT1 and its rat homolog, rOCT1. Furthermore there are
differences in the transport function of hOCT1 and a second human
organic cation transporter, hOCT2 (Gorboulev et al., 1997
).
Transiently transfected HeLa cells represent a useful tool for the
elucidation of the molecular mechanisms involved in the function of
hOCT1.
| |
Materials and Methods |
|---|
|
|
|---|
Construction and isolation of plasmid DNA for transfection.
hOCT1 cDNA was obtained by reverse transcriptase polymerase chain
reaction as described previously (Zhang et al., 1997b
). After gel purification, the polymerase chain reaction products were
ligated to the mammalian expression vector pTargeT (Promega, Madison,
WI) with T4 DNA ligase followed by transformation into DH5
competent
cells (Gibco, BRL, Gaithersburg, MD). The construct with the cDNA under
the CMV promoter (sense orientation), pTargeT-hOCT1, was identified by
restriction enzyme analysis and the sequence was confirmed by DNA
sequencing (Biomolecular Resource Center, UCSF, CA). Empty vector of
pTargeT was constructed by cutting the hOCT1 insert out of
pTargeT-hOCT1 with EcoRI followed by gel purification and
ligation. The construct of empty vector was confirmed by restriction
enzyme analysis.
20°C until use.
HeLa cell culture and transfection. HeLa cells were obtained from the UCSF Cell Culture Facility. Original stocks were from American Type Culture Collection (ATCC, Rockville, MD). Passages from 3 to 18 were used in the studies. The cells were grown at 37°C in a 5% CO2/95% air humidified atmosphere. The medium was Eagle's minimum essential medium with Earle's balanced salt supplemented with 2 mM glutamine, 100 IU/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml fungizone and 10% (vol/vol) fetal bovine serum. The cells were maintained in Nunc cell culture flasks (Nalge Nunc International, Naperville, IL). The cells were seeded at a density of 1.8 × 105 cells/well in 12-well tissue culture plates (Corning Costar Corp, Cambridge, MA) 24 hr before transfection. The cells were transfected with a cationic liposome technique by LipofectAMINE (2 mg/ml, Gibco, BRL) observing a modified protocol from Gibco, BRL. For each well, 100 µl Opti-MEM media (Gibco, BRL) was incubated with 2 µg DNA and another 100 µl Opti-MEM media with the lipid (4-8 µl; 7 µl for most of the experiments). The two solutions then were mixed together and incubated for 30 min at room temperature. After incubation, 800 µl Opti-MEM media was added to the previous mixture. The final mixture (1 ml) was applied to each well after rinsing the cells with the Opti-MEM media once. The cells were exposed to the lipid-DNA complex for 18 hr before replacing the transfection media with the fresh standard culture media.
Uptake measurements. The uptake studies were carried out between 24 and 72 hr post-transfection. Cells were incubated and washed with PBS once before the uptake studies. Subsequently, the cells were incubated at room temperature or 4°C (for temperature-dependence study) with 5 µM 14C-TEA (55 mCi/mmol, American Radiolabeled Chemicals, St. Louis, MO) in 0.5 ml of PBS. For Michaelis-Menten studies, various amounts of unlabeled TEA also were included in the reaction mixture. For inhibition and IC50 studies, various amounts of the tested compounds were included in the reaction mixture. Incubation was stopped by rinsing the cells once with 2 ml of ice-cold PBS and twice with 1 ml of ice-cold PBS buffer. After solubilizing the cells with 1 ml of 0.5% Triton X-100, 0.5 ml of sample was assayed by liquid scintillation counting (Beckman, Palo Alto, CA).
In trans-stimulation studies, each well of cells was preincubated with either 0.5 ml PBS (control) or 0.5 ml PBS plus the indicated concentration of unlabeled compounds at 37°C for 1 hr. Cells were then rinsed with 1 ml of ice-cold PBS twice before the uptake studies.Protein assay. For each plate used in the uptake study, two wells were saved for protein analysis. Cells were washed with PBS buffer and then solubilized with 0.5 ml of 1 N NaOH. After 2 hr, the solution was neutralized with 0.5 ml of 1 N HCl. 100 µl of solubilized cells were used for the protein assay with the Bio-Rad reagent (Bio-Rad, Hercules, CA). Absorbance was read at 595 nm, and the amount of protein was calculated from the standard curve generated by use of the known amounts of bovine serum albumin as standard.
Data analysis.
Uptake values are presented as mean ± standard deviation (S.D.) or mean ± standard error (S.E.) as
indicated in the figure legends. In each experiment, a minimum of two
wells was used to generate each data point, and each experiment was
repeated at least once. For Michaelis-Menten studies, data were fit to
the equation V = Vmax[S]/(Km + [S]) + Kns[S]
by nonlinear regression with Kaleidagraph Version 3.0 (Abelbeck
Software). V is the transport rate, [S] is the
substrate concentration and Kns is rate
constant of nonspecific uptake. Kns was
calculated from the rate constant of uptake in cells transfected with
empty vector. The IC50 was estimated by a
sigmoidal inhibition model and was fit to the equation V = V0/(1 + (I/IC50)n) by
nonlinear regression. V is the uptake of TEA in the presence of the inhibitor, V0 is the uptake of TEA
in the absence of inhibitor, I is the inhibitor
concentration and n is the slope. Data from nonlinear
regression are presented as mean ± error. For each compound, the
Ki was calculated from the corresponding
IC50 assuming a competitive inhibition; however,
because the ratio of 14C-TEA (5 µM)
concentration used in the inhibition studies to the Km of TEA (230 µM) was less than 5%,
Ki is virtually identical with
IC50 regardless of the inhibition model
(e.g., competitive versus noncompetitive) (Cheng
and Prusoff, 1973
). Statistical analysis was carried out by comparing
the treated to the controls from the same experiments by an unpaired
Student's t test (Primer of Biostatistics software, Version
3, written by Stanton A. Glantz, McGraw-Hill Companies, 1991), and a
value of P < .05 was considered significant.
Materials.
All the media and buffers used to maintain the
cells were obtained from the UCSF Cell Culture Facility unless
otherwise indicated. All chemicals were obtained from Sigma (St. Louis,
MO) and Fisher (Pittsburgh, PA) or as indicated.
R-(
)-disopyramide and S-(+)-disopyramide were
resolved as described previously to greater than 98% purity (Valdivieso et al., 1988
). 14C-TEA (55 mCi/mmol) was purchased from American Radiolabeled Chemicals (St.
Louis, MO). 3H-MPP+ (79.9 Ci/mmol) was purchased from DuPont NEN Research Products (Boston, MA),
and 3H-cimetidine (23.0 Ci/mmol) was purchased
from Amersham (Arlington Heights, IL).
| |
Results |
|---|
|
|
|---|
Initial characterization of hOCT1 expression in transiently
transfected HeLa cells.
The lipid to DNA ratio has been shown
previously to be important in the transient expression of the DNA
products in transfected cells (Hawley-Nelson et al., 1993
).
Initial titration studies with 1 to 3 µg lipid/µg DNA resulted in
no significant 14C-TEA uptake in the cells
transfected with pTargeT-hOCT1 versus untransfected cells
(data not shown). Significant uptake was observed in the transfected
cells when the lipid-to-DNA ratio ranged between 4:1 and 8:1 (the
highest lipid to DNA ratio tested). A lipid-to-DNA ratio of 7:1, 6.5:1
or 6:1, which resulted in the highest activity, was used in subsequent
studies. Because the 14C-TEA uptake in
mock-transfected cells (cells transfected with the empty vector) was
not significantly different from that in the untransfected cells, in
some experiments, untransfected cells were used as controls (see figure
legends).
|
|
Permeant studies. The rate of 14C-TEA uptake in the pTargeT-hOCT1-transfected cells was saturable, whereas the uptake rate in the empty vector-transfected cells was linear across the same concentration range (fig. 3). The Vmax and Km of TEA transport were 2.89 ± 0.448 nmol/mg protein/30 min and 229 ± 78.4 µM, respectively; and the Kns, the rate constant for the linear process, determined from TEA uptake in the empty vector-transfected cells was 2.46 pmol/mg protein/30 min/µM.
|
|
Inhibition studies.
To characterize the function of hOCT1
further, we studied 14C-TEA uptake in the
presence of various compounds at concentrations of 0.1 mM, 0.5 mM or 5 mM (fig. 5, A-D). At 0.1 mM, the organic cations, amantadine, clonidine, verapamil, quinine, quinidine, S-(+)-disopyramide and R-(
)-disopyramide
significantly inhibited C-TEA uptake (fig. 5A,
P < .05). In contrast, paraquat, dopamine and its precursors
(L-dopa and D-dopa) (not shown) did not
significantly affect the uptake of 14C-TEA. At
0.5 mM, cimetidine, choline, NMN, amantadine, dopamine, acebutolol,
(+)-nicotine, (
)-nicotine and midazolam significantly inhibited
14C-TEA uptake (fig. 5, B and C, P < .05),
whereas spermidine (polyamine), creatinine (zwitterion) and the organic
anion, PAH, did not produce any inhibition (fig. 5C). At high
concentrations (5 mM), paraquat, spermidine, L-dopa,
D-dopa and PAH (data not shown) did not produce significant
inhibition, whereas creatinine did (fig. 5D, P < .05). These data
indicate that hOCT1 is broadly selective for organic cations and some
other compounds, but not the organic anion, PAH, nor the multivalent
cations, paraquat and spermidine.
|
|
)-disopyramide, it was
15.4 ± 11.0 µM (fig. 6B) (P < .05).
|
Trans-stimulation studies. To determine whether hOCT1 can transport organic cations in both directions, trans-stimulation studies were performed. As shown in figure 7, after preincubation of the pTargeT-hOCT1-transfected HeLa cells with TEA (2 mM) or MPP+ (0.5 mM) for 1 hr at 37°C, 14C-TEA uptake was enhanced significantly (P < .05). The trans-stimulation also could be cis-inhibited more than 50% with 0.5 mM unlabeled TEA in the reaction media (data not shown). In contrast, preincubation of cells with 2 mM cimetidine did not result in a significant change in 14C-TEA uptake and preincubation of cells with 50 µM decynium-22 resulted in a significant decrease (apparent "trans-inhibition") of 14C-TEA uptake (P < .05).
|
| |
Discussion |
|---|
|
|
|---|
The present study demonstrates that hOCT1 can be expressed
functionally in a transiently transfected mammalian cell expression system (HeLa cells) by a lipofection method. Maximal TEA transport activity occurred between 36 and 48 hr (fig. 1) after transfection and
was observed when the lipid-to-DNA ratio was between 6:1 and 8:1 (data
not shown). In this system, TEA transport was temperature dependent and
was saturable with kinetic values similar to those obtained in X. laevis oocytes injected with the cRNA of hOCT1 (Zhang et
al., 1997b
) (Ki, 161 µM in HeLa
cells vs. 163 µM in oocytes). In addition, less than
2-fold differences in the Ki values of
decynium-22 and vecuronium were observed in cRNA-injected oocytes
(Zhang et al., 1997b
) and transfected HeLa cells (table 1),
which suggests that hOCT1 has similar functional characteristics in the
two expression systems.
A major goal of this study was to determine the functional
characteristics of hOCT1. In particular, the substrate selectivity of
the transporter was examined. Paraquat and spermidine are multivalent organic cations. Our data demonstrated that neither compound interacted with hOCT1 at 5 mM, which suggests that the transporter does not play a
role in the uptake of these compounds in human epithelia. These data
are consistent with data in the literature which demonstrate that
paraquat has a distinct transport pathway from TEA in the peritubular
membrane of the rabbit kidney (Groves et al., 1995
). The
data also suggest that the polyamine, spermidine, is not a substrate of
hOCT1, consistent with data in the literature which demonstrate unique
transporters for polyamines (Sokol and Gates, 1990
). Spermidine
previously was shown to induce inward currents in oocytes expressing
the rat homolog, rOCT1 (Busch et al., 1996
), which indicates
that spermidine may be translocated by rOCT1. The data suggest that
there are interspecies differences in the function of the OCT1
transporters. However, recent studies demonstrated that a compound
(e.g., quinine) could induce large inward currents without
being translocated (Nagel, et al., 1997
). Further studies are needed to determine whether spermidine is a substrate for rOCT1.
Although spermidine and paraquat did not interact with hOCT1, the
multivalent organic cation, vecuronium interacts in micromolar
concentrations (Ki = 232 µM), which
suggests that the nature of the hydrophobic moiety may play a role in
the potency of interaction of multivalent organic cations with hOCT1.
We determined the effect of the neutral molecules, corticosterone and
midazolam, on the transport of 14C-TEA
via hOCT1. Previously, corticosterone was thought to enter the cell via simple diffusion to gain access to its sites of
action. However it is becoming increasingly clear that transporters may be involved in the entry of corticosterone into cells. For example, corticosterone has been shown to interact with both organic cation and
organic anion transport in the microperfused kidney (Ullrich et
al., 1993
), and recently, has been shown to interact specifically with the rat liver organic anion transporter (oatp) (Bossuyt et al., 1996
; Kanai et al., 1996
), and the rat organic
cation transporter, rOCT1 (Grundemann et al., 1994
, 1997
).
The present study demonstrated that corticosterone is a potent
inhibitor of TEA uptake mediated by hOCT1. Further studies are needed
to determine whether corticosterone is an actual substrate or whether
it inhibits, but is not translocated by hOCT1.
The neutral compound, midazolam, is a cytochrome P450 3A (CYP3A)
substrate with a Km of approximately 10 µM for 1'-hydroxymidazolam formation (Wrighton and Ring, 1994
). The
Ki of midazolam in inhibiting TEA transport
by hOCT1 is in the same range of its Km of
metabolism by CYP3A. Because hOCT1 is expressed primarily in the liver,
which is the major site for the metabolism of midazolam, it is possible that transport rate limits the metabolism of midazolam. Collectively, these data indicate that hOCT1 is polyspecific not only for organic cations but also for various neutral compounds. The positive charge(s) of a molecule may not be the only structural requirement for
interaction with hOCT1 as previously hypothesized for OCT transporters.
The hydrophobic moiety also may play a role in the potency of
interaction of a chemical entity with hOCT1. Further structure-function
relationship studies are needed to clarify this.
Numerous xenobiotics are chiral and contain one or more asymmetric
carbon atoms, which results in two or more enantiomeric forms. There
are many examples of differences in pharmacological activity between
enantiomeric compounds (Blaschke and Giacomini, 1987
; Drayer, 1986
;
Levy and Boddy, 1991
). Stereoselective metabolism of xenobiotics has
been well studied and documented (Drayer, 1986
; Levy and Boddy, 1991
).
In this study, we examined the potency of the interaction of various
isomers in inhibiting TEA uptake in hOCT1-transfected cells. Within the
two pairs tested, the diastereoisomers, quinine and quinidine, had no
significant differences in IC50 values (23.4 ± 6.94 µM vs. 17.9 ± 4.69 µM) whereas
S-(+)-disopyramide was approximately 2-fold less potent than
R-(
)-disopyramide (29.9 ± 8.50 µM vs.
15.4 ± 11.0 µM). These data suggest that hOCT1 is not highly
stereoselective, which is consistent with the polyspecificity of the
transporter.
Ki values of various compounds in
inhibiting TEA or MPP+ uptake mediated by hOCT1
(Gorboulev et al., 1997
; Zhang et al., 1997b
) and
rOCT1 (Grundemann et al., 1994
, 1997
; Martel, 1996
)
(i.e., between species) are listed in table
2. Ki values
of TEA, MPP+, desipramine and clonidine in
interacting with hOCT1 and rOCT1 are similar (within 3-fold). In
contrast, most of the other organic cations studied, including
decynium-22, procainamide, NMN, quinine and vecuronium, have much
higher Ki values (more than 3-fold) for
hOCT1 than for rOCT1. These data indicate that in comparison with rats,
humans possess an organic cation transporter with a lower affinity for
most compounds, which suggests that in human epithelial cells organic
cations translocated primarily by OCT1 transporters will be eliminated
more slowly than in rats. For example, it has been shown previously
that the organic cation vecuronium is transported at a considerably
slower rate in human hepatocytes than in rat hepatocytes (Sandker
et al., 1994
). Higher Ki values
of vecuronium for hOCT1 than for rOCT1 may explain in part its slower
transport rate in humans. The steroid, corticosterone, however, has a
higher affinity for hOCT1 than for rOCT1, which may suggest that
cholesterol compounds will have more potent interaction with organic
cation transport in humans than in rats. However, further studies are
needed to determine whether the interacting compounds are actual
substrates of OCT1 transporters and not simply inhibitors. Moreover, it
will be essential to study the site-specific localization of the OCT1
and the relative amounts of the transporters expressed in various
tissues.
|
Comparisons were made between Ki values of
various compounds in interacting with the organ-specific transporters
in humans, hOCT1 (expressed primarily in liver) (Gorboulev et
al., 1997
; Zhang et al., 1997b
) and hOCT2 (expressed
primarily in kidney) (Gorboulev et al., 1997
) (table 2).
hOCT2 apparently has a higher affinity for most of the organic cations
studied except for desipramine, which seems to have lower affinity for
hOCT2 than for hOCT1. Thus, it appears that the kidney-specific organic
cation transporter, hOCT2, more potently interacts with potential
substrates than the liver-specific transporter, hOCT1.
Previous studies have shown that the transport of organic cations
via hOCT1 can be driven by a favorable (inside negative) electrical potential difference (Zhang et al., 1997b
).
However, it is not known whether transport of organic cations may also be driven by the exchange or countertransport of other organic cations.
Our data demonstrate that 14C-TEA transport can
be driven by the countertransport of unlabeled TEA (fig. 7), which
suggests that hOCT1 may operate as an organic cation/organic cation
exchanger. In addition, the ability of a compound to
trans-stimulate the transport of
14C-TEA mediated by hOCT1 indicates that the
compound also is translocated by the transporter. The finding that
MPP+ trans-stimulated
14C-TEA transport is consistent with previous
studies in oocytes which demonstrated that MPP+
is a substrate of hOCT1 (Zhang et al., 1997b
). However,
because of the high background uptake of
3H-MPP+ in the empty
vector-transfected cells, an enhanced uptake of H-MPP+ was not observed in
the hOCT1-transfected cells. The finding that cimetidine did not
trans-stimulate TEA uptake, consistent with results from
permeant studies, indicates that cimetidine is not a good permeant of
hOCT1 under the experimental conditions (fig. 4). In contrast,
decynium-22 was shown to "trans-inhibit" TEA uptake,
which suggests that decynium-22 binds tightly to the transporter and is
not washed off during the experimental procedures. Alternatively, hOCT1
loaded with decynium-22 cycles more slowly than the unloaded
transporter. Collectively, these data suggest that hOCT1 is a uniporter
which can translocate organic cations in both directions. When
radiolabeled compounds are not available, trans-stimulation
studies provide an alternative way of determining whether a chemical
entity is a substrate for the transporter.
In summary, hOCT1 has been transiently expressed in a mammalian cell line, HeLa. The fundamental properties of TEA transport in this system are similar to those previously described in X. laevis oocytes. Using this expression system, studies were conducted which demonstrated the selectivity of the transporter for a variety of substrates. Differences in the Ki values of certain compounds in interacting with the rat and the human organic cation transporters, and the human liver-specific versus kidney-specific organic cation transporters were observed. This study provides the first information about the molecular basis for the differences in organic cation transport observed among species and organs. The development of this mammalian expression system will facilitate the study of drug interactions and transport in vitro and the development of drugs that specifically target cells that express hOCT1.
| |
Footnotes |
|---|
Accepted for publication March 6, 1998.
Received for publication November 20, 1997.
1 This study was supported by grants from the National Institutes of Health (GM-36780 and GM-57656).
2 Supported in part by the UCSF Chancellor's Research Fellowship.
Send reprint requests to: Kathleen M. Giacomini, Ph.D., Department of Biopharmaceutical Sciences, Box 0446, University of California, San Francisco, San Francisco, CA 94143-0446.
| |
Abbreviations |
|---|
OCT, organic cation transporter; TEA, tetraethylammonium; MPP+, 1-methyl-4-phenylpyridinium; NMN, N1-methylnicotinamide; PAH, p-aminohippuric acid; dopa, 3, 4-dihydroxyphenylalanine; PBS, phosphate-buffered saline.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Z. Yuan, A. Tie, M. Tarnopolsky, and M. Bakovic Genomic organization, promoter activity, and expression of the human choline transporter-like protein 1 Physiol Genomics, September 14, 2006; 26(1): 76 - 90. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. White, V. A. Saunders, P. Dang, J. Engler, A. C. W. Zannettino, A. C. Cambareri, S. R. Quinn, P. W. Manley, and T. P. Hughes OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib Blood, July 15, 2006; 108(2): 697 - 704. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Biermann, D. Lang, V. Gorboulev, H. Koepsell, A. Sindic, R. Schroter, A. Zvirbliene, H. Pavenstadt, E. Schlatter, and G. Ciarimboli Characterization of regulatory mechanisms and states of human organic cation transporter 2 Am J Physiol Cell Physiol, June 1, 2006; 290(6): C1521 - C1531. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Michel, Z. Yuan, S. Ramsubir, and M. Bakovic Choline Transport for Phospholipid Synthesis. Experimental Biology and Medicine, May 1, 2006; 231(5): 490 - 504. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kwok, A. Yamauchi, R. Rajesan, L. Chan, U. Dhillon, W. Gao, H. Xu, B. Wang, S. Takahashi, J. Semple, et al. Carnitine/xenobiotics transporters in the human mammary gland epithelia, MCF12A Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R793 - R802. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Bourdet, J. B. Pritchard, and D. R. Thakker Differential Substrate and Inhibitory Activities of Ranitidine and Famotidine toward Human Organic Cation Transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3) J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1288 - 1297. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Engel and J. Wang Interaction of Organic Cations with a Newly Identified Plasma Membrane Monoamine Transporter Mol. Pharmacol., November 1, 2005; 68(5): 1397 - 1407. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Gorboulev, N. Shatskaya, C. Volk, and H. Koepsell Subtype-Specific Affinity for Corticosterone of Rat Organic Cation Transporters rOCT1 and rOCT2 Depends on Three Amino Acids within the Substrate Binding Region Mol. Pharmacol., May 1, 2005; 67(5): 1612 - 1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Thomas, L. Wang, R. E. Clark, and M. Pirmohamed Active transport of imatinib into and out of cells: implications for drug resistance Blood, December 1, 2004; 104(12): 3739 - 3745. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hashimoto, S. Narikawa, X.-L. Huang, T. Minematsu, T. Usui, H. Kamimura, and H. Endou CHARACTERIZATION OF THE RENAL TUBULAR TRANSPORT OF ZONAMPANEL, A NOVEL {alpha}-AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONIC ACID RECEPTOR ANTAGONIST, BY HUMAN ORGANIC ANION TRANSPORTERS Drug Metab. Dispos., October 1, 2004; 32(10): 1096 - 1102. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Wright and W. H. Dantzler Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport Physiol Rev, July 1, 2004; 84(3): 987 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hasannejad, M. Takeda, K. Taki, H. J. Shin, E. Babu, P. Jutabha, S. Khamdang, M. Aleboyeh, M. L. Onozato, A. Tojo, et al. Interactions of Human Organic Anion Transporters with Diuretics J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1021 - 1029. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Jonker and A. H. Schinkel Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3) J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 2 - 9. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kaewmokul, V. Chatsudthipong, K. K. Evans, W. H. Dantzler, and S. H. Wright Functional mapping of rbOCT1 and rbOCT2 activity in the S2 segment of rabbit proximal tubule Am J Physiol Renal Physiol, December 1, 2003; 285(6): F1149 - F1159. [Abstract] [Full Text] |
||||
![]() |
Y. Shu, M. K. Leabman, B. Feng, L. M. Mangravite, C. C. Huang, D. Stryke, M. Kawamoto, S. J. Johns, J. DeYoung, E. Carlson, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 PNAS, May 13, 2003; 100(10): 5902 - 5907. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Bednarczyk, S. Ekins, J. H. Wikel, and S. H. Wright Influence of Molecular Structure on Substrate Binding to the Human Organic Cation Transporter, hOCT1 Mol. Pharmacol., March 1, 2003; 63(3): 489 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Burckhardt, S. Brai, S. Wallis, W. Krick, N. A. Wolff, and G. Burckhardt Transport of cimetidine by flounder and human renal organic anion transporter 1 Am J Physiol Renal Physiol, March 1, 2003; 284(3): F503 - F509. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Leazer and C. D. Klaassen The Presence of Xenobiotic Transporters in Rat Placenta Drug Metab. Dispos., February 1, 2003; 31(2): 153 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Khamdang, M. Takeda, R. Noshiro, S. Narikawa, A. Enomoto, N. Anzai, P. Piyachaturawat, and H. Endou Interactions of Human Organic Anion Transporters and Human Organic Cation Transporters with Nonsteroidal Anti-Inflammatory Drugs J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 534 - 539. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Cova, U. Laforenza, G. Gastaldi, Y. Sambuy, S. Tritto, A. Faelli, and U. Ventura Guanidine Transport across the Apical and Basolateral Membranes of Human Intestinal Caco-2 Cells Is Mediated by Two Different Mechanisms J. Nutr., July 1, 2002; 132(7): 1995 - 2003. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Enomoto, M. Takeda, M. Shimoda, S. Narikawa, Y. Kobayashi, Y. Kobayashi, T. Yamamoto, T. Sekine, S. H. Cha, T. Niwa, et al. Interaction of Human Organic Anion Transporters 2 and 4 with Organic Anion Transport Inhibitors J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 797 - 802. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kimura, M. Takeda, S. Narikawa, A. Enomoto, K. Ichida, and H. Endou Human Organic Anion Transporters and Human Organic Cation Transporters Mediate Renal Transport of Prostaglandins J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 293 - 298. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Takeda, S. Khamdang, S. Narikawa, H. Kimura, Y. Kobayashi, T. Yamamoto, S. H. Cha, T. Sekine, and H. Endou Human Organic Anion Transporters and Human Organic Cation Transporters Mediate Renal Antiviral Transport J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 918 - 924. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Shu, C. L. Bello, L. M. Mangravite, B. Feng, and K. M. Giacomini Functional Characteristics and Steroid Hormone-Mediated Regulation of an Organic Cation Transporter in Madin-Darby Canine Kidney Cells J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 392 - 398. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Jonker, E. Wagenaar, C. A. A. M. Mol, M. Buitelaar, H. Koepsell, J. W. Smit, and A. H. Schinkel Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene Mol. Cell. Biol., August 15, 2001; 21(16): 5471 - 5477. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Burckhardt and N. A. Wolff Structure of renal organic anion and cation transporters Am J Physiol Renal Physiol, June 1, 2000; 278(6): F853 - F866. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhang, W. Gorset, C. B. Washington, T. F. Blaschke, D. L. Kroetz, and K. M. Giacomini Interactions of HIV Protease Inhibitors with a Human Organic Cation Transporter in a Mammalian Expression System Drug Metab. Dispos., March 1, 2000; 28(3): 329 - 334. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Dresser, A. T. Gray, and K. M. Giacomini Kinetic and Selectivity Differences between Rodent, Rabbit, and Human Organic Cation Transporters (OCT1) J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1146 - 1152. [Abstract] [Full Text] |
||||
![]() |
L. Zhang, W. Gorset, M. J. Dresser, and K. M. Giacomini The Interaction of n-Tetraalkylammonium Compounds with a Human Organic Cation Transporter, hOCT1 J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1192 - 1198. [Abstract] [Full Text] |
||||
![]() |
G. Pietig, T. Mehrens, J. R. Hirsch, I. Cetinkaya, H. Piechota, and E. Schlatter Properties and Regulation of Organic Cation Transport in Freshly Isolated Human Proximal Tubules J. Biol. Chem., August 31, 2001; 276(36): 33741 - 33746. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||